TG Therapeutics: What Wall Street Isn't Telling You [Seeking Alpha]
TG Therapeutics, Inc. (TGTX)
Last tg therapeutics, inc. earnings: 11/12 07:34 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.tgtherapeutics.com
Company Research
Source: Seeking Alpha
In my opinion, it's Briumvi that has the best efficacy among anti-CD20 monoclonal antibodies, including Ocrevus and Kesimpta. Thanks to the increased demand for Briumvi, TG Therapeutics' EBIT margin increased by 3% year-on-year to 18.2%. In this article, you'll learn about additional factors that explain why I'm initiating coverage of TG Therapeutics with a Buy rating. koto_feja/E+ via Getty Images TG Therapeutics, Inc. ( TGTX ) is becoming a prominent player in the multiple sclerosis therapeutics market thanks to its Briumvi [ ublituximab ], an anti-CD20 monoclonal antibody. To my surprise, its shares have fallen 33.2% over the past eight months This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than fr
Show less
Read more
Impact Snapshot
Event Time:
TGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TGTX alerts
High impacting TG Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TGTX
News
- TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Investing in TG Therapeutics (NASDAQ:TGTX) three years ago would have delivered you a 160% gain [Yahoo! Finance]Yahoo! Finance
- TG Therapeutics (NASDAQ:TGTX) had its "hold (c+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- TG Therapeutics (NASDAQ:TGTX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TGTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZeMarketBeat
- TG Therapeutics (NASDAQ:TGTX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TGTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street MarketBeat
TGTX
Earnings
- 11/3/25 - Beat
TGTX
Sec Filings
- 1/9/26 - Form 4
- 1/9/26 - Form 4
- 11/25/25 - Form 4
- TGTX's page on the SEC website